Loading stock data…
60 Degrees Pharmaceuticals (SXTP)
$1.78+0.17 (+10.56%)
After Hours$1.72-0.06 (-3.12%)· Last close Jun 29
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
60 Degrees Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.78 with a market capitalization of $4M. Wall Street consensus targets $3.70 (1 analysts), implying a +107.9% move over the next 12 months. The stock is currently near its 52-week low of $1.22, remaining 44.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 74 is overbought against a weak tape. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +107.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 74 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $162,092↓ | $303,385↓ | $437,602↑ | $100,932↓ | $163,552 |
| Gross Profit | $76,377↓ | $182,703↑ | -$100,088↓ | $50,881↓ | $90,280 |
| Operating Income | -$2.09M↓ | -$1.92M↑ | -$2.33M↓ | -$1.60M↑ | -$1.91M |
| Net Income | -$2.09M↓ | -$1.44M↑ | -$2.32M↓ | -$1.73M↑ | -$1.88M |
Peer Comparison
JNJUNHPFE
Fundamentals
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-156.92%
Volume
Today's trading volume
159,677
Recent News
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +50.00% and +33.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -33.33% and -3.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should Know
60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODA
60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) is one of the best up and coming penny stocks to buy. On February 2, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to enhance the affordability and accessibility of ARAKODA (tafenoquine), the only FDA-approved, once-weekly prescription medication for malaria prevention in the US. The collaboration allows eligible patients to […]
Is GoodRx (GDRX) Using ARAKODA Discounts To Quietly Redefine Its Preventive Care Strategy?
In February 2026, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to offer eligible U.S. consumers savings of up to 30% on ARAKODA, the only FDA-approved, once-weekly prescription malaria prevention, across more than 70,000 pharmacies and home delivery where available. This collaboration broadens GoodRx’s presence in travel-related preventive care, linking its discount platform to a specialized medication for malaria risk management. Next, we’ll examine how expanding into...